Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnenolone in Alcohol Use Disorder
NCT03872128Phase 1Completed
- Sponsor
- Yale University
- Start
- Sep 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pregnenolone in alcohol use disorder (AUD) (3 arms), sponsored by Yale University. Primary endpoints: Percent Drinking Days at 8 weeks, Percent Heavy Drinking Days at 8 weeks and 1 more. Started Sep 2018; status: completed.
02
Drugs
pregnenolone
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03872128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872128.